Cabenuva

Manufacturer Product Website

This analysis supports the therapeutic potential of CAB + RPV Q8W for virologically suppressed people living with HIV-1 infection seeking an alternative maintenance treatment option to daily oral SoC.

The study examined the safety, tolerability and acceptability of the drug in adolescents living with HIV-1. Results from the study showed that the drug’s safety and efficacy were similar to those established in cabotegravir plus rilpivirine administered in adults.

Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients.

With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.

Oral cabotegravir + rilpivirine demonstrated efficacy in the majority of participants and an acceptable safety profile through 6 years of treatment, demonstrating its durability as maintenance therapy for HIV-1.

A Phase 2b, multicenter, open-label, rollover study.

This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.

The combination of cabotegravir and rilpivirine is a new, long-acting once monthly injectable treatment option for people living with human immunodeficiency virus (HIV).

Cabotegravir/rilpivirine is a novel form of therapy that has the potential to impact the lives of many patients living with HIV-1 who struggle with nonadherence. There are advantages and disadvantages which should be taken into consideration, as previously discussed. Ultimately, the decision to initiate cabotegravir/rilpivirine should be a shared decision making process between the patient